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Introduction
Human CYP2A6 is responsible for the metabolic activation of tobacco-related nitrosamines, such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Tiano et al., 1993) and the metabolism of nicotine (Nakajima et al., 1996) . In addition, CYP2A6 catalyzes the metabolism of coumarin and several pharmaceutical agents such as tegafur, losigamone, and letrozole (Nakajima et al., 2002) . There is a large interindividual variability in CYP2A6 activity and expression, mainly due to genetic polymorphisms. Many studies have revealed that the interindividual variability in CYP2A6 activity affects smoking behavior or cancer susceptibility (Nakajima, 2007; Strasser et al., 2007; Fujieda et al., 2004) . In addition to polymorphisms, large interindividual variability was observed within the homozygotes of the wild type CYP2A6 gene (Nakajima et al., 2006) . Non-genetic factors contributing to this variability have been proposed, including administration of drugs, exposure to environmental chemicals, diet, and sex hormone have been proposed (Koudsi et al., 2010) . These can be partly explained by the activation of transcriptional factors such as pregnane X receptor (Itoh et al., 2006) , glucocorticoid receptor (Onica et al., 2010) , nuclear factor-erythroid 2 related factor 2 (Yokota et al., 2011) , and estrogen receptor (Higashi et al., 2007) .
To expand the understanding of the regulation of CYP2A6 expression, we sought to investigate the possibility of its regulation through a microRNA (miRNA). miRNAs, an evolutionarily conserved class of endogenous ~ 22-nucleotide noncoding RNAs, bind to the 3'-untranslated region (3'-UTR) of target mRNAs causing translational repression or mRNA degradation (Bartel, 2004) . To date, over 2,500 miRNAs have been identified in humans, and it has been estimated that 60% of human mRNA could be targeted by miRNAs (Bartel, 2004; Friedman et al., 2009) . Previously, we found that miRNAs regulate human xenobiotic-metabolizing enzymes such as CYP1B1 (Tsuchiya et al., 2006) and CYP2E1 (Mohri et al., 2010) . Another research group reported that human CYP2C8 is also regulated by miRNAs (Zhang et al., 2012) . Kalscheuer et al. (2008) reported that rat CYP2A3, showing high sequence similarity to human CYP2A6, is regulated by miR-126*, whose expression in the lung was decreased by administration of NNK for 20 weeks. This report prompted us to This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on February 20, 2015 as DOI: 10.1124 at ASPET Journals on June 21, 2017 dmd.aspetjournals.org Downloaded from DMD#63225 5 examine whether human CYP2A6 might also be regulated by miR-126* because the miRNA recognition element (MRE) of miR-126* is highly homologous to the MRE of CYP2A3 mRNA.
CYP2A7, another member of the human CYP2A subfamily, shows 96.5% nucleotide identity with CYP2A6. CYP2A7 mRNA is substantially expressed in the human liver (Koskela et al., 1999) , but the protein product is functionally inactive because it cannot incorporate heme (Ding et al., 1995; Yamano et al., 1990) . Because CYP2A7 mRNA has an MRE for miR-126* and is perfectly matched to that of the CYP2A6 mRNA, we investigated the possibility that CYP2A7 mRNA may act as a decoy for binding of miR-126* to modulate CYP2A6 expression. DMD#63225 site, downstream of the luciferase gene in the pGL3-promoter vector. The sequence from +1718 to +1738 of the human CYP2A6 mRNA (5'-ATG CTA TGA AGA GTA GTA ATA-3') was termed the MRE. A fragment containing the sequence from +1691 to +1744 of the CYP2A6 mRNA containing the MRE was cloned into the pGL-3 promoter vector, resulting in a forward insertion (pGL3/MRE) and a reverse insertion (pGL3/MRE-Rev). A fragment containing the perfectly matching sequence with the mature miR-126*, 5'-CTA GAC GCG TAC CAA AAG TAA TAA TGT-3' (the matching sequence of miR-126* is italicized), was cloned into the pGL3-promoter vector (pGL3/c-miR-126*).
Human CYP2A6 cDNA was amplified by PCR using a reverse-transcribed product from RNA of a human liver sample with the forward primer 5′-CCA CCA TGC TGG CCT CAG GG-3′ and the reverse primer 5′-GCT CAG CGG GGC AGG AAG-3′. This cDNA fragment was cloned into the pTARGET vector, resulting in the pTARGET/CYP2A6 plasmid. The 3'-UTR of CYP2A6 was amplified by PCR using human genome DNA with the forward primer 5′-AAA ATG GGC ATG AAC GCC C-3′ and the reverse primer 5′-CAA GTG TAC CTG GCA GGA AA-3′. This fragment was cloned into the pTARGET vector (pTARGET/3'-UTR). The CYP2A6 coding region digested from pTARGET/CYP2A6 was cloned into the pTARGET/3'-UTR, resulting in the pTARGET/CYP2A6+UTR. Human CYP2A7 cDNA including the 3′-UTR was amplified by PCR using a reverse-transcribed product from RNA of a human liver sample with the forward primer 5′-CCA CCA TGC TGG CCT CAG GG-3′ and the reverse primer 5′-TCA GGA AAT AAG AGC TGC T-3′. The amplified fragment was cloned into the pTARGET vector, resulting in the pTARGET/CYP2A7 plasmid.
Cell culture and luciferase assay
MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Nissui
Pharmaceutical, Tokyo, Japan) supplemented with 0.1 mM nonessential amino acids (Invitrogen) and 10% fetal bovine serum (FBS; Invitrogen). HEK293 cells were cultured in DMEM containing 4.5 g/liter glucose, 10 mM HEPES, and 10% FBS. Human cryopreserved This article has not been copyedited and formatted. The final version may differ from this version. Various luciferase reporter plasmids (pGL3) were transiently transfected with phRL-TK plasmid into MCF-7 cells. Briefly, the day before transfection, cells were seeded onto 24-well plates at a density of 5 × 10 4 cells/well. After 24 h, 490 ng of pGL3 plasmid, 10 ng of phRL-TK plasmid and the precursors for miR-126* or control were co-transfected using Lipofectamine 2000. After incubation for 48 h, the cells were lysed with a passive lysis buffer and then the luciferase activity was measured with a luminometer (Wallac, Turku, Finland) using the dual-luciferase reporter assay system.
Establishment of two HEK293 cell lines stably expressing human CYP2A6 including or excluding the 3'-UTR
HEK293 cells were seeded onto 24-well plates, and 500 ng of pTARGET/CYP2A6+UTR or pTARGET/CYP2A6 plasmids were transfected using Lipofectamine 2000 according to the manufacturer's protocols. Forty-eight hours after transfection, the cells were passaged and subsequently grown in medium containing 400 mg/ml G418, and diluted from 1:10 to 1:1000.
The selective medium was replaced every 3-4 days and individual G418-tolerable colonies were selected after 2 weeks in culture. Tolerable clones were screened by Western blot analysis and coumarin 7-hydroxylase activity. We confirmed that the CYP2A6 protein levels and enzyme activity were sustained regardless of the repeated subculture.
Transfection of precursor for miR-126* and CYP2A7 expression plasmid into HEK/2A6+UTR or HEK/2A6 cells and preparation of cell homogenates and total RNA
The precursor miRNA was transfected into HEK/2A6+UTR or HEK/2A6 cells as follows:
the day before transfection, the cells were seeded onto 6-well plates at a density of 5 × 10 5 cells/well. After 24 h, 50 nM precursor for miR-126* or control was transfected into HEK/2A6+UTR cells and HEK/2A6 cells using Lipofectamine RNAiMAX. When 100, 500 or This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on February 20, 2015 as DOI: 10.1124 at ASPET Journals on June 21, 2017 dmd.aspetjournals.org Downloaded from DMD#63225 9 1000 ng pTARGET/CYP2A7 and precursor miRNA were transiently co-transfected, Lipofectamine2000 was used instead of Lipofectamine RNAiMAX. After incubation for 48 h, the cells were harvested and suspended in a small amount of TGE buffer [10 mM Tris-HCl, 20% glycerol, 1 mM EDTA (pH 7.4)] and disrupted by freeze-thawing three times. Total RNA was prepared using RNAiso and then treated with 5 U/µg RNA DNase I to remove plasmid DNA as needed according to the manufacturer's protocol.
Transfection of precursor for miR-126*, AsO for miR-126* and siRNA for CYP2A7 into human hepatocytes
The precursor miRNA, AsO and siRNA were transfected into primary human hepatocytes as follows: after 6 h of seeding human hepatocytes onto 6-well plates at a density of 5 × 10 5 cells/well, 50 nM precursor for miR-126* or control, 10 nM AsO for miR-126* or control and 5 nM siRNA for CYP2A7 or control were transfected into the cells using Lipofectamine RNAiMAX. After 24 h incubation, the cells were harvested and total cell homogenates and total RNA were prepared as described above.
Determination of the half-life of CYP2A6 mRNA
The HEK/2A6+UTR cells and HEK/2A6 cells were transfected with precursor for miR-126* or control as described above and were simultaneously treated with 2 μg/mL α-amanitin. Total RNA was prepared 2, 4, 6 and 8 h later. The CYP2A6 mRNA levels were determined by real time RT-PCR as described below.
Preparation of homogenates, total RNA and genomic DNA from 20 human liver samples
Human liver samples (Supplemental Table 1) 
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Iwate Medical University (Morioka, Japan) (HG H20-4). Homogenates were prepared from the human liver samples by homogenization with lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40) containing protease inhibitors (0.5 mM (p-amidinophenyl) methanesulfonyl fluoride, 2 μg/ml aprotinin, 2 μg/ml leupeptin). The protein concentrations were determined using the Bradford protein assay reagent (Bio-Rad, Hercules, CA) with γ-globulin as a standard. Total RNA was prepared using RNAiso according to the manufacturer's protocols, and the integrity was confirmed by estimating the ratio of the band density of 28S and 18S rRNA. Genomic DNA was extracted using the Puregene DNA isolation kit (Qiagen, Tokyo, Japan).
SDS-PAGE and western blot analyses of CYP2A6
Total cell homogenates from HEK/2A6+UTR cells or HEK/2A6 cells (20-30 μg) and human liver homogenates (5-50 μg) were separated by 7.5% SDS-PAGE and transferred to an Immobilon-P transfer membrane (Millipore, Billerica, MA). The membranes were probed with mouse anti-human CYP2A6, rabbit anti-human β-actin or rabbit anti-human GAPDH primary antibodies and the corresponding fluorescent dye-conjugated secondary antibodies. The band densities were quantified with the Odyssey Infrared Imaging system (LI-COR Biosciences).
The CYP2A6 protein levels were normalized to the β-actin or GAPDH protein levels.
Coumarin 7-hydroxylase activity
Coumarin 7-hydroxylase activity was determined as follows: a typical incubation mixture (final volume of 0.2 mL) contained 50 mM potassium phosphate buffer (pH 7.4), 1 μM coumarin, and 40 μg/mL total cell homogenates from HEK/2A6+UTR cells or HEK/2A6 cells.
The reaction was initiated by the addition of NADPH-generating systems (0.5 mM NADP + , 5 mM glucose-6-phosphate, 5 mM MgCl 2, and 1 U/mL glucose-6-phosphate dehydrogenase) after a 2-min preincubation at 37°C. After a 15 min incubation at 37°C, the reaction was terminated by the addition of 20 μL of ice-cold 10% perchloric acid. After removal of the protein by centrifugation at 15,000 rpm for 5 min, a portion of the supernatant was subjected to This article has not been copyedited and formatted. The final version may differ from this version. high-performance liquid chromatography (HPLC). The HPLC analyses were performed using an L-2100 pump (Hitachi, Tokyo, Japan), an L-2200 autosampler (Hitachi), an L-2485 fluorescence detector (Hitachi), and a D-2500 integrator (Hitachi) equipped with a Mightysil RP-18 (4.6 × 150 mm; 5 µm) column (Kanto Chemical, Tokyo, Japan). The eluate was monitored with the excitation wavelength set at 320 nm and emission at 415 nm. The mobile phase was 15% acetonitrile containing 20 mM perchloric acid. The flow rate was 1.0 mL/min.
The column temperature was 35°C. The quantification of the metabolites was performed by comparing the HPLC peak height with that of authentic standards.
Genotyping of CYP2A6 alleles
The genotyping of CYP2A6*4 (Fukami et al., 2007) and CYP2A6*9 (Nakajima et al., 2006) for 20 human liver samples was performed as described previously.
Real-time RT-PCR for CYP2A6
The cDNA was synthesized from total RNA prepared from cells or human liver samples. The expression levels of mature miR-126* were determined by using the TaqMan microRNA assay (Applied Biosystems, Foster City, CA). The cDNA templates were prepared using the TaqMan microRNA Reverse Transcription kit, which utilizes the stem-loop reverse primers according to the manufacturer's protocols. After the reverse transcription reaction, the product was mixed with TaqMan Universal PCR Master Mix and TaqMan MicroRNA assay containing the forward and reverse primers as well as the TaqMan probe for miR-126*. The PCR conditions were as follows: after an initial denaturation at 95 °C for 10 min, the amplification was performed by denaturation at 95 °C for 15 s, annealing and extension at 60 °C for 60 s for 40 cycles. The expression levels of U6 small nuclear RNA (U6 snRNA) were also determined by using the TaqMan microRNA assay and were used to normalize the miR-126* levels.
Statistical analysis
Statistical significance was determined by analysis of variance followed by Dunnett's multiple comparisons test. Comparison of two groups was made with an unpaired, two-tailed Student's t test. Correlation analyses were performed by Pearson's product-moment method.
When the P value was less than 0.05, the differences were considered to be statistically significant.
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Results
Luciferase assay to investigate whether the MRE on the CYP2A6 3'-UTR is functional
By computational search, we found an MRE of miR-126* on the CYP2A6 3'-UTR (+1670 to +1723), the sequence of which is highly homologous to the MRE of CYP2A3 mRNA (Fig.   1A ). To investigate whether the MRE is functional, a luciferase assay using reporter plasmids containing a fragment including the MRE was performed with MCF-7 cells. Since the miR-126* level in MCF-7 cells was marginal, the cell line was selected to examine the effects of overexpression of the miR-126*. When the pGL3/c-miR-126* plasmid containing the miR-126* complementary sequence was assayed, luciferase activity was significantly (P < 0.001) decreased (18% of control) by the co-transfection of the precursor for miR-126*, suggesting that the overexpressed miR-126* was functional. The luciferase activity of the pGL3/MRE plasmid was significantly (P < 0.01) decreased (66% of control), whereas that of the pGL3/MRE-Rev plasmid was not (Fig. 1B) . These results suggest that miR-126* functionally recognizes the MRE in the human CYP2A6 3'-UTR.
Effects of overexpression of miR-126* on CYP2A6 protein level, enzyme activity and mRNA level in HEK293 expression systems
To examine whether miR-126* downregulates CYP2A6 expression, HEK293 cell lines stably expressing human CYP2A6 including ( Fig. 2A) or excluding the 3'-UTR ( Fig. 2B) (HEK/2A6+UTR and HEK/2A6 cells, respectively) were established. In these cell lines, the expression level of miR-126* was marginal (Ct value: 29.2). When the precursor for miR-126* was transfected into HEK/2A6 +UTR cells, the CYP2A6 protein level was significantly (P < 0.05) decreased (38% of NT) (Fig. 2C) . In contrast, in the HEK/2A6 cells, CYP2A6 protein levels tended to be decreased, although the difference was statistically insignificant (Fig. 2D) .
The coumarin 7-hydroxylase activity was significantly decreased by the overexpression of miR-126* in HEK/2A6+UTR cells (59% of NT and 57% of control, P < 0.05) ( Fig. 2E ) and in HEK/2A6 cells (64% of NT, P < 0.01) (Fig. 2F) . When the miR-126* was overexpressed in This article has not been copyedited and formatted. The final version may differ from this version. HEK/2A6+UTR cells, the CYP2A6 mRNA level was significantly (P < 0.001) decreased (51% of NT and 47% of control) (Fig. 2G) , whereas it was marginally decreased in HEK/2A6 cells ( Fig. 2H) . These results suggest that the 3'-UTR including the MRE plays an important role in the miR-126*-dependent down-regulation of CYP2A6.
Effects of overexpression of miR-126* on CYP2A6 mRNA stability
To investigate whether miR-126* facilitates the degradation of the CYP2A6 mRNA, cells transfected with the precursor for miR-126* were treated with α-amanitin, and CYP2A6 mRNA levels were determined at different time points. The half-life of CYP2A6 mRNA in the HEK/2A6+UTR cells (Fig. 3A) and HEK/2A6 cells (Fig. 3B ) was calculated to be 4.3 h and 8.9 h, respectively, and it was not affected by the overexpression of miR-126*. Thus, the finding that the half-life of CYP2A6 mRNA in HEK/2A6+UTR cells was shorter than in HEK/2A6 cells is interesting, but the miR-126* appeared to have no effect on CYP2A6 mRNA stability.
Effects of overexpression or inhibition of miR-126* on CYP2A6 expression levels in primary human hepatocytes
We investigated whether miR-126* downregulates endogenous CYP2A6 expression in human hepatocytes. As shown in Fig. 4A and B , the overexpression and inhibition of miR-126* significantly (P < 0.01) decreased (74% of control) and increased (2.0-fold) CYP2A6 protein levels, respectively. The CYP2A6 mRNA levels were not affected by either treatment (Figs. 4C and D) . These results suggest that the endogenous CYP2A6 in human hepatocytes is regulated by miR-126* through translational repression.
Relationship between the expression levels of CYP2A6 mRNA, CYP2A6 protein,
CYP2A7 mRNA and miR-126* in the human liver
To evaluate the significance of the miR-126*-dependent downregulation of CYP2A6 in human livers, we examined the relationship between the expression levels of CYP2A6 mRNA, To investigate whether CYP2A7 mRNA inhibits the downregulation of CYP2A6 via miR-126*, pTARGET/CYP2A7 and miR-126* were co-transfected into HEK/2A6+UTR cells which hardly express endogenous CYP2A7. When 100, 500, and 1000 ng pTARGET/CYP2A7 was transfected into HEK/2A6+UTR cells, the CYP2A7 mRNA copy numbers resulted in approximately 0.4, 2.9, and 8.7 times higher expression than that of CYP2A6 mRNA, respectively (Fig. 8A) . These CYP2A7/CYP2A6 mRNA ratios were within the range of those in human livers. The CYP2A7 mRNA levels in any condition were significantly (P < 0.01) decreased (53-62% of control) by overexpression of miR-126*, suggesting that CYP2A7 is also regulated by miR-126*. Interestingly, the expressed CYP2A7 restored the miR-126*-dependent downregulation of CYP2A6 protein (Fig. 8B) and mRNA (Fig. 8C ) levels when 1000 ng pTARGET/CYP2A7 was transfected, although 100 and 500 ng pTARGET/CYP2A7 had no effects. These results suggest that CYP2A7 mRNA affects CYP2A6 expression by acting as a decoy for binding of miR-126* when the CYP2A7 mRNA expression level is much higher than that of CYP2A6.
To examine whether endogenous CYP2A7 affects CYP2A6 expression level as a miRNA decoy, siCYP2A7 was transfected into primary human hepatocytes. CYP2A7 mRNA was remarkably decreased to 26%, but the knockdown of CYP2A7 mRNA (Fig. 9A ) did not affect CYP2A6 mRNA (Fig. 9B ) or protein levels (Fig. 9C ). CYP2A7 mRNA levels may be too low to inhibit miR-126*-dependent down-regulation of CYP2A6 in these human hepatocytes as the CYP2A7/CYP2A6 mRNA ratio was 1.0. Although we could not expand this study, CYP2A7 would function as a decoy for miR-126* in hepatocytes in which CYP2A7 mRNA expression levels are much higher than those of CYP2A6. This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 7) . Although untested, studies using multiple lots of human primary hepatocytes would strengthen the presumption that CYP2A7 interferes with the miR-126*-dependent downregulation of CYP2A6 in human hepatocytes.
The miR-126* gene is within the intron 7 of the epidermal growth factor-like domain 7 gene on human chromosome 9. The miR-126* has been reported to be decreased in lung cancer (Yanaihara et al., 2009) . Decreased miR-126* may increase CYP2A6 in lung cancer, which would result in the augmentation of metabolic activation of tobacco-related nitrosamines. It would be of interest to compare miR-126* levels as well as CYP2A6 expression in lung cancerous tissue versus in non-cancerous tissues. CYP2A13, which is expressed in the lung, has a similar MRE as the one for miR-126*. We performed a luciferase assay using a reporter construct containing the MRE of the CYP2A13 mRNA. Luciferase activity was decreased by miR-126* (data not shown), suggesting that CYP2A13 is also regulated by miR-126*.
Previously, we reported that CYP2A13 expression was higher in non-small cell lung carcinomas than in adjacent noncancerous tissue (Fukami et al., 2010) . Although we did not measure the miR-126* levels in these samples, it would be interesting to determine whether the difference in CYP2A13 expression levels might be due to differences in miR-126* expression.
The current study revealed that the half-life of the CYP2A6 mRNA in HEK/2A6+UTR cells was shorter than that in HEK/2A6 cells (Figs. 3A and B ), suggesting that CYP2A6 3'-UTR plays an important role in CYP2A6 mRNA stability. Previously, it has been reported that the half-life of the mRNA derived from CYP2A6*1B, a CYP2A6 variant allele in which a part of sequence in the 3'-UTR (+1533 to +1589) is converted to a corresponding sequence of the DMD#63225 DMD#63225 DMD#63225 DMD#63225 
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